drugset / Trial / NCT03963414
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
Timeline
- Start
- 2020-09-25
- Primary completion
- 2021-12-15
- Completion
- 2021-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 75 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |